Massey scientists seek to improve stem cell transplant outcomes through computer modeling of next generation sequencing data
Scientists at VCU Massey Cancer Center’s award-winning Bone Marrow Transplant (BMT) Program recently published several studies that support the possibility of using next-generation DNA sequencing and mathematical modeling to not only understand the variability observed in clinical outcomes of stem cell transplantation, but also to provide a theoretical framework to make transplantation a possibility for more patients who do not have a related donor.
The Cancer Research and Resource Center of Southern Virginia in Danville has moved to a new location that is more accessible to cancer patients, survivors and their families and caregivers. After four years at the Institute for Advanced Learning and Research, the office now resides in Danville’s Main Street community at Kennedy Hall, 103 S. Main Street, formerly part of Stratford College.
VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) researchers discovered a unique approach to treating pancreatic cancer that may be potentially safe and effective. The treatment method involves immunochemotherapy – a combination of chemotherapy and immunotherapy, which uses the patient’s own immune system to help fight against disease. This pre-clinical study, led by Paul B. Fisher, M.Ph., Ph.D., and Luni Emdad, M.B.B.S., Ph.D., found that the delivery of [pIC]PEI – a combination of the already-established immune-modulating molecule, polyinosine-polycytidylic acid (pIC), with delivery molecule polyethlenimine (PEI), a polymer often used in detergents, adhesives and cosmetics – inside pancreatic cancer cells triggers cancer cell death without harming normal pancreatic cells.
Innovative national clinical trial offered at Massey utilizes precision medicine techniques to improve lung cancer treatment
VCU Massey Cancer Center is conducting a novel clinical trial in collaboration with the National Cancer Institute and cancer centers nationwide for patients with squamous cell lung cancer, a type of non-small cell lung cancer with different genetic changes driving the growth of cancerous cells. These genetic changes vary from person to person, and this clinical trial, named Lung-MAP, is unique in offering a targeted approach to better treat the patient.
Last week, the National Cancer Institute (NCI) hosted a Twitter chat on precision medicine in lung cancer. Danielle Shafer, D.O., hematologist-oncologist, member of the Developmental Therapeutics research program at Massey Cancer Center and assistant professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine, provided expert commentary as Dr. Shakun Malik, head of thoracic oncology therapeutics for the NCI’s Cancer Therapy Evaluation Program, posed a series of questions and discussion topics.